6-K 1 d259607d6k.htm 6-K 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of report: December 7, 2021

Commission File Number: 001-39387

 

 

Renalytix plc

(Translation of registrant’s name into English)

 

 

Finsgate

5-7 Cranwood Street

London EC1V 9EE

United Kingdom

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒  Form 20-F            ☐  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 


INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On December 7, 2021, Renalytix plc (the “Company”) published an operational update and financial results for the three months ended September 30, 2021, which are furnished as Exhibit 99.1 to this Report on Form 6-K.

The Unaudited Condensed Consolidated Balance Sheets, Statements of Operations and Comprehensive Loss, Statements of Shareholders’ Equity and Cash Flows and the Notes to Unaudited Interim Condensed Consolidated Financial Statements contained in Exhibit 99.1 are hereby incorporated by reference into the Company’s Registration Statement on Form S-8 (Registration No. 333-248741).

EXHIBIT INDEX

 

Exhibit

   Description
99.1    Operational Update and Financial Results for the Three Months Ended September 30, 2021.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

RENALYTIX PLC
By:   /s/ James McCullough
  James McCullough
  Chief Executive Officer

Date: December 7, 2021